CompanyAEONNYSEAliso Viejo, CA

AEON Biopharma, Inc.

AEON Biopharma develops ABP-450, a botulinum toxin biosimilar targeting therapeutic indications including movement disorders and pain conditions.

SEC EDGAR ClinicalTrials.gov aeonbiopharma.com

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

AEON gets FDA Type 2b feedback on ABP-450 biosimilar pathway for BOTOX

Sep 30Quarterly updateAEON Biopharma, Inc.onabotulinumtoxina

August 2026

AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450

Aug 12FinancingAEON Biopharma, Inc.

July 2026

AEON Biopharma closes $13.75 million offering with attached milestone warrants

Jul 15FinancingAEON Biopharma, Inc.